Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of composition of Artalbic acid derivatives in preparation of erythropenia anemia resistant drug

A low red blood cell and composition technology, which can be used in drug combinations, medical preparations containing active ingredients, extracellular fluid diseases, etc., and can solve problems such as insufficient hematopoietic raw materials or utilization barriers

Inactive Publication Date: 2016-11-09
南京海澳斯生物医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] (3) Anemia caused by insufficient hematopoietic raw materials or utilization disorders
[0017] 1) Folic acid or B vitamins 12 Anemia caused by deficiency or utilization disorder Megaloblastic anemia caused by absolute or relative deficiency or utilization disorder of folic acid or vitamin B12 due to various physiological or pathological factors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of composition of Artalbic acid derivatives in preparation of erythropenia anemia resistant drug
  • Application of composition of Artalbic acid derivatives in preparation of erythropenia anemia resistant drug
  • Application of composition of Artalbic acid derivatives in preparation of erythropenia anemia resistant drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] The preparation of embodiment 1 compound Artalbic acid

[0033] The preparation method of compound Artalbic acid (I) refers to the literature published by Antonella Maggio et al. (Antonella Maggio et al., 2011. Artalbic acid, a sesquiterpene with an unusual skeleton from Artemisia alba (Asteraceae) from Sicily. Tetrahedron Letters, 52 (2011) 4543–4545) approach.

[0034]

Embodiment 2

[0035] The synthesis of the O-bromoethyl derivative (II) of embodiment 2 Artalbic acid

[0036] Compound I (266 mg, 1.00 mmol) was dissolved in 10 mL of benzene, and tetrabutylammonium bromide (TBAB) (0.08 g), 1,2-dibromoethane (3.760 g, 20.00 mmol) and 6 mL of 50% sodium hydroxide solution. The mixture was stirred at 40 °C for 16 h. After 16 hours, the reaction solution was poured into ice water, extracted twice with dichloromethane immediately, and the organic phase solutions were combined. Then the organic phase solution was washed with water and saturated brine for 5 times successively, then dried with anhydrous sodium sulfate, and finally concentrated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: petroleum ether / acetone=100:1.0, v / v), the brown concentrated elution band was collected and the solvent was evaporated to obtain a brown powder of Compound II (272mg, 73...

Embodiment 3

[0041] The synthesis of O-(dichloroethylamino) ethyl derivative (III) of embodiment 3 Artalbic acid

[0042] 1. Synthesis of O-(dihydroxyethylamino)ethyl derivatives of Artalbic acid

[0043]Compound II (187 mg, 0.5 mmol) was dissolved in 20 mL of acetonitrile, anhydrous potassium carbonate (690 mg, 5.0 mmol), potassium iodide (252 mg, 1.5 mmol) and diethanolamine (1051 mg, 10 mmol) were added thereto, and the mixture was heated to reflux for 1 h. After the reaction was completed, the reaction solution was poured into 20 mL of ice water, extracted three times with an equal amount of dichloromethane, and the organic phases were combined. The combined organic phases were successively washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography (mobile phase: petroleum ether / acetone=100:1.0, v / v), and the yello...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of composition of O-(dichloro ethylamino) ethyl and O-(bis(2-methylthio ethyl)amino) ethyl derivatives of Artalbic acid in preparation of an erythropenia anemia resistant drug, and relates to the fields of organic synthesis and medicinal chemistry, in particular to composition of the O-(dichloro ethylamino) ethyl and O-(bis(2-methylthio ethyl)amino) ethyl derivatives of Artalbic acid, a preparation method of the composition and an application of the composition in preparation of the erythropenia anemia resistant drug. The invention discloses the composition of the O-(dichloro ethylamino) ethyl and O-(bis(2-methylthio ethyl)amino) ethyl derivatives of Artalbic acid and the preparation method of the composition. Pharmacological experiments indicate that the composition of the O-(dichloro ethylamino) ethyl and O-(bis(2-methylthio ethyl)amino) ethyl derivatives of Artalbic acid has the erythropenia anemia resistant function and has the value in development of the erythropenia anemia resistant drug.

Description

technical field [0001] The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to a composition, a preparation method and an application thereof. Background technique [0002] There are different classifications of anemia based on different clinical features. Such as: acute and chronic anemia according to the progress of anemia; proliferative anemia (such as hemolytic anemia, iron deficiency anemia, megaloblastic anemia, etc.) and hypoplastic anemia (such as aplastic anemia) ). [0003] Clinically, it is often classified from the pathogenesis and etiology of anemia: [0004] 1. Anemia with reduced erythropoiesis [0005] The abnormality of hematopoietic cells, bone marrow hematopoietic microenvironment and hematopoietic raw materials affect erythropoiesis, which can form erythropoietic anemia. [0006] (1) Anemia caused by abnormal hematopoietic stem and progenitor cells [0007] 1) Aplastic anemia (AA) AA is a bone marrow hematop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/195C07C217/12C07C323/25A61P7/06
CPCA61K31/195C07C217/12C07C323/25
Inventor 丁秋菊
Owner 南京海澳斯生物医药科技有限公司